|
 |
VitraveneThis page contains recent news articles, when available, and an overview of Vitravene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Isis is pioneering the effort into antisense research and has already commercialized an antisense drug in 1998 with Vitravene. Isis has several proprietary ... Seeking Alpha (blog) ISIS Gains from TEVA-OGXI Deal - Dec 29, 2009 Isis is pioneering the effort into antisense research and has already commercialized an antisense drug in 1998 with Vitravene. Isis has several proprietary ... Zacks.com Making Sense of Antisense and Its Rebound Potential - Nov 13, 2009 Vitravene for cytomegalovirus retinitis was launched over 20 years ago. Yet companies and investors remain committed to antisense therapeutic development. ... Genetic Engineering News (press release) Paul Zamecnik dies - Nov 9, 2009 One antisense drug, Isis Pharmaceutical's Vitravene, was commercialized in 1998 to treat cytomegalovirus retinitis in AIDS patients, and several others are ... Scientist Antisense—down, but not out - Apr 30, 2007 The approval of Isis' Vitravene, a 21-base phosphorothioate ... After its early success with Vitravene, however, Isis suffered several reverses. ... Nature.com Antisense and Sensibility in RNA Therapeutics - Jan 17, 2005 The drug, called Vitravene, is used to treat cytomegalovirus retinitis in ... Generating little more than $150000 annually,[1] Vitravene is no blockbuster. ... Scientist Isis to delay cholesterol drug data; shares drop - Apr 28, 2008 Isis currently has only one drug, Vitravene, in the market. Vitravene treats a condition called cytomegalovirus (CMV) retinitis -- which causes the ... Reuters US Asks for Cholesterol Drug Data - Apr 26, 2008 Isis currently has only one drug, Vitravene, in the market. Vitravene treats a condition called cytomegalovirus retinitis, which causes inflammation of the ... New York Times Isis posts narrower-than-expected Q2 loss - Aug 7, 2008 O), currently has only one drug, Vitravene, in the market. Vitravene treats a condition that causes the inflammation of the eye's retina. ... Reuters Challenges and Opportunities for Local and Systemic Delivery of siRNA... - Aug 5, 2008 ASOs represent the most mature therapeutic platform, with one approved product—Vitravene (fomivirsen sodium), for cytomegalovirus-induced retinitis—and more ... Nature.com Carlsbad biotech goes on a tear - Oct 14, 2007 Isis has brought one antisense drug to market, called Vitravene. ... Approved for sale in 1997, Vitravene was a proof of concept for Isis; the drug's sales ... North County Times Isis Breathes Life into Asthma Drug Development - Apr 27, 2005 It's federally approved antisense drug, Vitravene, is marketed by ... Vitravene treats an eye disease called cytomegalovirus retinitis in AIDS patients. ... SanDiego.com The Sweet Smell of Biotech Success - Jan 8, 2005 ...based Isis Pharmaceuticals launched the antisense drug Vitravene for HIV-related cytomegalovirus infection in 1998, but the success of protease inhibitors ... Scientist å??义è?¯ç‰©å¸‚场å‰?景ä¹?观 - Apr 18, 2007 Vitravene为注射剂，患者æ¯?月å?ªéœ€æ³¨å°„一次è?¯ç‰©(利用专用针头直接注射进眼ç?ƒå†…)，有 效率高达80ï¼…~90％。紧éš?ISISå…¬å?¸ä¹‹å?Žï¼Œç¾Žå›½Eyetech制è?¯å…¬å?¸äºŽ2001年上市了第二个 ... ä¸é‡‘在线 Isis reports lower losses, drug development progress. - May 13, 2008 The company has spent hundreds of millions of dollars in research and development of antisense, but received approval for just one antisense drug, Vitravene ... $9.94 - Knight Ridder/Tribune Business News - Alacra Store Germ Sensors - Feb 13, 2006 Over the past 12 months Isis--which has just one commercial drug, Vitravene, a treatment for retinal virus infections that is marketed by Novartis--lost ... Forbes Isis says experimental drug fights bad cholesterol - Nov. 12, 2006 - Nov 12, 2006 Isis has a drug on the market called Vitravene, a treatment for HIV-related vision problems, which is licensed by the Swiss drug giant Novartis (Charts). ... CNNMoney.com Antisense suffers new setback - Nov 2, 2006 Since the 1998 FDA approval of Isis Pharmaceuticals' Vitravene (fomivirsen) for treating certain viral eye infections in AIDS patients, no other antisense ... Nature.com Isis Pharmaceuticals to Cut 40% of Jobs - Jan 11, 2005 Isis, the maker of the Vitravene drug for an AIDS-related eye disorder, intends to reduce its workforce to about 300 people from more than 460 employees, ... Pay-Per-View - Los Angeles Times - ProQuest Archiver The Nature Biotechnology shortlist of nominees - Mar 2, 2006 Developers of the first antisense drug Vitravene (fomivirsen) approved in 1998. Paul Carter, Leonard Presta and Mark Sliwkowksi. ... Nature.com Isis to trim 165 workers to save cash - Jan 11, 2005 Although Isis scored a minor success with the approval in 1998 of Vitravene, a little-prescribed drug to treat AIDS-related blindness, other antisense-drug ... San Diego Union - Tribune - San Diego Union Tribune Guidelines for Antisense Oligonucleotide Design and Insight Into... - Jul 4, 2008 In fact, an RNase H–inducing AON is registered under the name Vitravene to treat cytomegaloviral-induced retinitis, and many AONs aiming at targeted gene ... Nature.com Stock Spotlight: Bad cholesterol down, stock up | Article from... - Nov 14, 2006 Isis Pharmaceuticals' Vitravene is the first "antisense" drug to be reviewed by the Food and Drug Administration. Created from ... ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Dice tener la fórmula de la inmortalidad - Jun 12, 2005 Como ejemplos, Kurzweil menciona el vitravene, un medicamento comercializado en el mercado estadounidense que manipula el proceso de expresión de genes ... elmundo.es ISIS Pharmaceuticals Inc. is Added to Watch List. - Mar 27, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Free with registration - M2 Presswire - AccessMyLibrary.com Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Bristol-Myers,... - Jun 8, 2007 The company has already commercialized the first antisense drug in 1998 with Vitravene. Isis has several proprietary compounds in clinical development as ... Free with registration - Business Wire - AccessMyLibrary.com In- Depth Research On ISIS Pharmaceuticals Inc. - Dec 4, 2006 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Free with registration - M2 Presswire - AccessMyLibrary.com Analysis of ISIS Pharmaceuticals Inc. - Mar 22, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... $4.95 - M2 Presswire - ECNext Antisense drugs stop making sense? - Dec 18, 2006 This was Isis Pharmaceuticals' Vitravene (fomivirsen), a treatment for cytomegalovirus retinitis (CMV) in immunocompromised patients, such as those with ... DrugResearcher.com 5 Stocks Approaching Greatness - Jul 16, 2008 It has one antisense drug, Vitravene, on the market. -Best "anti-sense" pharmaceutical company in the business, having produced the only FDA-approved ... fool.com Antivirals cope with influenza, cytomegalovirus and varicella-zoster... - May 1, 2005 Cidofovir - Vistide 5 mg/kg IV once/wk x 2 then 5 mg/kg IV q2wks Fomivirsen - Vitravene 330 mcg intravitreally q2wks x 2 then 1x/mo DRUGS COST (1) Val. Free with registration - Managed Healthcare Executive - AccessMyLibrary.com Market Commentary on ISIS Pharmaceuticals Inc. - Jan 17, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... $4.95 - M2 Presswire - ECNext Isis, Rosetta Ink Deal to Develop miRNA-Targeting Drugs and Ambion … - Feb 23, 2006 Thus far, Isis has only brought one to market, Vitravene, which is used to treat cytomegalovirus retinitis in AIDS patients — a relatively small patient ... genomeweb.com Interest in antisense waning, but not dead.(Friday, September... - Sep 19, 2005 If approved, Genasense could be the light bulb for the field, although Isis has gotten one antisense drug to the market: Vitravene, which gained EDA ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones Research and Markets: Acuity Pharmaceuticals and Sirna Therapeutics … - Apr 5, 2006 Companies have been testing ASOs in the clinic for ten years, and one antisense product, fomivirsen (Isis Pharmaceuticals' Vitravene), is on the market. ... Genetic Engineering News - Genetic Engineering News (press release) Licensing deal.(RXs)(Genzyme Corp. licensing agreement with Isis … - Jul 14, 2008 Isis Pharmaceuticals Inc. has been given approval to market Vitravene, a drug that treats disease by "switching off" genes. ... Pay-Per-View - Chain Drug Review - HighBeam Research Press Release: Analysis of ISIS Pharmaceuticals Inc. - M2 Presswire |... - Mar 22, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Pay-Per-View - M2 Presswire - HighBeam Research Germ Sensors - Jan 31, 2006 Over the past 12 months Isis--which has just one commercial drug, Vitravene, a treatment for retinal virus infections that is marketed by Novartis--lost ... RedOrbit Ophthalmology; Evolving guidelines for intravitreous injections... - Jan 11, 2005 While only fomivirsen sodium (Vitravene) is currently approved by the Food and Drug Administration as an IVT injection, the number of approved IVT ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Press Release: ISIS Pharmaceuticals Inc. is Added to Watch List. - M2... - Mar 27, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Pay-Per-View - M2 Presswire - HighBeam Research Emerging Markets Consulting, LLC. : Emerging Equity Alerts. - Nov 14, 2006 The company markets its antisense drug, Vitravene, for the treatment of cytomegalovirus and retinitis in AIDS patients. Its products under Phase 1 include ... Free with registration - M2 Presswire - AccessMyLibrary.com Press Release: Market Commentary on ISIS Pharmaceuticals Inc. - M2 … - Jan 29, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Pay-Per-View - M2 Presswire - HighBeam Research Isis Pharmaceuticals Announces Collaboration With Pfizer to Discover ... - May 24, 2005 ..."Isis has already shown that antisense drugs can be effective in treating ocular diseases, having discovered and developed Vitravene(R). ... $4.95 - PR Newswire - ECNext Yellow-white retinal lesion in a 48-year-old woman.(Photo Quiz) - Aug 15, 2007 Intravitreal injection of ganciclovir, foscarnet, or fomivirsen (Vitravene; brand not available in the United States) allows for direct delivery of the drug ... $4.95 - American Family Physician - ECNext Ophthalmology; Evolving guidelines for intravitreous injections... - Jan 15, 2005 While only fomivirsen sodium (Vitravene) is currently approved by the Food and Drug Administration as an IVT injection, the number of approved IVT ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Significant Technological Challenges Remain for the Development of … - Feb 2, 2006 Companies have been testing ASOs in the clinic for ten years, and one antisense product, fomivirsen (Isis Pharmaceuticals' Vitravene), is on the market. ... $4.95 - M2 Presswire - ECNext Press Release: Market Commentary on ISIS Pharmaceuticals Inc. - M2 … - Jan 17, 2007 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: ISIS to operate SurgiMedia across Europe. - M2 … - Aug 4, 2006 PR Newswire; September 16, 1998 ; 700+ words ... ... marketing of Vitravene(TM) in Europe. Isis Pharmaceuticals, based in northern ... novel human ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Market Commentary on ISIS Pharmaceuticals Inc. - M2 … - Nov 9, 2006 Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. ... Pay-Per-View - M2 Presswire - HighBeam Research Nagroda Nobla w dziedzinie fizjologii i medycyny za rok 2006 - Dec 6, 2006 Warto jednak podać przykÅ‚ad już zarejestrowanego leku (fomiwirsen, Vitravene), który jest przeznaczony do leczenia zapalenia siatkówki spowodowanego ... Medycyna Praktyczna Clinical relevance of alternative splicing.(Review Article) - May 1, 2006 The antisense drug first to date is Vitravene for CMV retinitis, approved by US FDA in the year 1998.[77] Many antisense oligonucleotides have been ... Free with registration - Indian Journal of Human Genetics - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |